A noncovalent complex vaccine prepared with detoxified Escherichia coli J5 (Rc chemotype) lipopolysaccharide and Neisseria meningitidis group B outer membrane protein produces protective antibodies against gram-negative bacteremia

Journal of Infectious Diseases

Volumn 173, Issue 5, 1996, Pages 1157-1163

  Bhattacharjee, Apurba K ^a   Opal, Steven M ^c   Taylor, Robert ^c   Naso, Robert ^c   Semenuk, Mark ^c   Zollinger, Wendell D ^c   Moran, Ellen E ^c   Young, Lynnette ^c   Hammack, Craig ^c   Sadoff, Jerald C ^c   Cross, Alan S ^b  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; IMMUNOGLOBULIN G ANTIBODY; OUTER MEMBRANE PROTEIN;

ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; GRAM NEGATIVE SEPSIS; INTRAMUSCULAR DRUG ADMINISTRATION; NEISSERIA MENINGITIDIS; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RABBIT; RAT; VACCINE PRODUCTION;

EID: 19144369410     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/173.5.1157     Document Type: Article

References (15)

1. Centers for Disease Control and Prevention. Increase in national hospital discharge survey rates for septicemia-United States, 1979-1987. MMWR 1990;39:31-4.
2. Bone RC, Fisher CJ, Clemmer TP, et al. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987;317:653-8.
3. Chedid L, Parant M, Parant F, Boyer F. A proposed mechanism for natural immunity to enterobacterial pathogens. J Immunol 1968;100:292-301.
4. McCabe WR. Immunization with R mutants of S. minnesota. I. Protection against challenge with heterologous gram-negative bacilli. J Immunol 1972;108:601-10.
5. Braude AI, Ziegler EJ, McCutchan JA, Douglas H. Immunization against nosocomial infection. Am J Med 1981;70:463-6.
6. Ziegler EJ, McCutchan JA, Fierer J, et al. Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med 1982;307:1225-30.
7. Ashcroft MT, Nicholson CC, Balwant S, Ritchie JM, Soryan E, William F. A seven year field trial of two typhoid vaccines in Guiana. Lancet 1967;2:1056-9.
8. Miller DL, Alderslade R, Ross EM. Whooping cough vaccine: the risks and benefits debate. Epidemiol Rev 1982;4:1-24.
9. Collins HH, Cross AS, Dobeck A, Opal SM, McClain JB, Sadoff JC. Oral ciprofloxacin and a monoclonal antibody to lipopolysaccharide protect leukopenic rats from lethal infection with Pseudomonas aeruginosa. J Infect Dis 1989;159:1073-82.
10. Bhattacharjee AK, Opal SM, Palardy JE, et al. Affinity-purified Escherichia coli J5 lipopolysaccharide-specific IgG protects neutropenic rats against gram-negative bacterial sepsis. J Infect Dis 1994;170:622-9.
11. Westphal O, Jann K. Bacterial lipopolysaccharides. Extraction with phenol-water and further applications of the procedure. Methods Carbohydr Chem 1965;5:83-91.
12. Zollinger WD, Mandrell RE, Grifiss JM, Altieri P, Berman S. Complex of meningococcal group B polysaccharide and type 2 outer membrane protein immunogen in man. J Clin Invest 1979;63:836-48.
13. Zollinger WD, Boslego J, Moran E, et al. Process for the preparation of detoxified polysaccharide-outer membrane protein complexes and their use as antibacterial vaccines. US patent 4,707,543. 17 November 1987.
14. Bhattacharjee AK, Jennings HJ, Kenny CP, Martin A, Smith ICP. Structural determination of the sialic acid polysaccharide antigens of Neisseria meningitidis serogroup B and C with carbon-13 nuclear magnetic resonance. J Biol Chem 1975;250:1926-32.
15. Holst O, Muller-Loennies S, Lidner B, Brade H. Chemical structure of the lipid A of Escherichia coli J5. Eur J Biochem 1993;214:695-701.